PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
18.78%
Revenue growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 6.14%. Joel Greenblatt would investigate if growth quality matches quantity.
3.89%
Cost growth 50-90% of Drug Manufacturers - Specialty & Generic median of 6.37%. Mohnish Pabrai would examine sustainable cost advantages.
49.59%
Gross profit growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 6.46%. Joel Greenblatt would investigate competitive advantages.
25.94%
Margin change of 25.94% versus flat Drug Manufacturers - Specialty & Generic margins. Walter Schloss would verify quality.
4.80%
R&D change of 4.80% versus flat Drug Manufacturers - Specialty & Generic spending. Walter Schloss would verify adequacy.
10.60%
G&A change of 10.60% versus flat Drug Manufacturers - Specialty & Generic overhead. Walter Schloss would verify efficiency.
-24.93%
Marketing expense reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate competitive implications.
-53.22%
Other expenses reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate advantages.
-0.97%
Operating expenses reduction while Drug Manufacturers - Specialty & Generic median is -0.17%. Seth Klarman would investigate advantages.
2.07%
Total costs growth 50-90% of Drug Manufacturers - Specialty & Generic median of 3.46%. Mohnish Pabrai would examine discipline.
61.86%
Interest expense change of 61.86% versus flat Drug Manufacturers - Specialty & Generic costs. Walter Schloss would verify control.
5.29%
D&A growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.24%. Jim Chanos would check for overinvestment.
262.69%
EBITDA growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 7.03%. Joel Greenblatt would investigate advantages.
-20.53%
EBITDA margin decline while Drug Manufacturers - Specialty & Generic median is 1.18%. Seth Klarman would investigate causes.
190.40%
Operating income growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 6.58%. Joel Greenblatt would investigate advantages.
176.11%
Operating margin growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.69%. Joel Greenblatt would investigate advantages.
10539.46%
Other expenses growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 2.24%. Jim Chanos would check for issues.
211.19%
Pre-tax income growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 13.36%. Joel Greenblatt would investigate advantages.
193.61%
Pre-tax margin growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 6.03%. Joel Greenblatt would investigate advantages.
363.97%
Tax expense growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 11.32%. Jim Chanos would check for issues.
171.27%
Net income growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 13.39%. Joel Greenblatt would investigate advantages.
160.00%
Net margin growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 4.18%. Joel Greenblatt would investigate advantages.
162.90%
EPS growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 15.15%. Joel Greenblatt would investigate advantages.
162.90%
Diluted EPS growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 15.09%. Joel Greenblatt would investigate advantages.
2.26%
Share count reduction below 50% of Drug Manufacturers - Specialty & Generic median of 0.09%. Jim Chanos would check for issues.
2.43%
Diluted share reduction below 50% of Drug Manufacturers - Specialty & Generic median of 0.10%. Jim Chanos would check for issues.